REVANCE THERAPEUTICS LTD
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 597
- Market Cap
- $685.5M
- Website
- http://www.revance.com
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 303
- Registration Number
- NCT03014622
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 306
- Registration Number
- NCT03014635
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 2691
- Registration Number
- NCT03004248
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02973269
- Locations
- 🇺🇸
Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02706795
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States
🇺🇸Precision Research Organization, Miami Lakes, Florida, United States
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT02580370
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02565732
Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 268
- Registration Number
- NCT02303002
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2014-01-31
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01940991
- Locations
- 🇺🇸
Dermatology Research Institute, Coral Gables, Florida, United States
Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 311
- Registration Number
- NCT01818076
- Locations
- 🇺🇸
Nashville Centre for Laser and Facial Surgery, Nashville, Tennessee, United States
© Copyright 2024. All Rights Reserved by MedPath